Transgene Biotek Intrinsic Value
Transgene Biotek intrinsic value. Transgene Biotek (TRABI) median intrinsic value is ₹2.11 from 1 valuation models (range ₹2–₹2), vs current price ₹2.49 — -15.3% downside (Trading Above Median Value), margin of safety -18.0%. Browse Transgene Biotek annual reports for revenue, profit, balance sheet and cash flow data.
TRABI Valuation Methods Summary — DCF, Graham Number & P/E
Transgene Biotek intrinsic value across 1 models vs current price ₹2.49 — upside/downside and value range per method. For current market price and key ratios, visit TRABI share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹2.11 | ₹1.90 - ₹2.32 | -15.3% | Book Value/Share: ₹1.05, P/B: 2.0x |
TRABI Intrinsic Value vs Market Price — All Valuation Models
Transgene Biotek fair value range ₹2–₹2 vs current market price ₹2.49 across 1 valuation models. Analyse TRABI shareholder distribution to track promoter, FII and institutional holdings.
TRABI Intrinsic Value Analysis — Undervalued or Overvalued?
Transgene Biotek median intrinsic value ₹2.11, current price ₹2.49 — Trading Above Median Value by 15.3%, margin of safety -18.0%.
What is the intrinsic value of TRABI?
Based on our comprehensive analysis using 1 different valuation methods, the estimated intrinsic value of Transgene Biotek (TRABI) is ₹2.11 (median value). With the current market price of ₹2.49, this represents a -15.3% variance from our estimated fair value.
The valuation range spans from ₹2.11 to ₹2.11, indicating ₹2.11 - ₹2.11.
Is TRABI undervalued or overvalued?
Based on our multi-method analysis, Transgene Biotek (TRABI) appears to be trading above median value by approximately 15.3%.
TRABI Financial Health — Key Ratios vs Industry Benchmarks
Transgene Biotek financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | -50.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -560.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
TRABI Cash Flow Quality — Operating & Free Cash Flow
Transgene Biotek operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1 Cr | ₹0 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |